Assessment of pancreatitis associated with tocilizumab use using the United States Food and Drug Administration Adverse Event Reporting System database.
Adverse Drug Reaction Reporting Systems
/ statistics & numerical data
Aged
Antibodies, Monoclonal, Humanized
/ adverse effects
Female
Humans
Male
Middle Aged
Pancreatitis
/ chemically induced
Receptors, Interleukin-6
/ antagonists & inhibitors
Retrospective Studies
United States
United States Food and Drug Administration
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
22 09 2021
22 09 2021
Historique:
received:
21
06
2021
accepted:
07
09
2021
entrez:
23
9
2021
pubmed:
24
9
2021
medline:
18
12
2021
Statut:
epublish
Résumé
Tocilizumab (TCZ) is used to treat rheumatoid arthritis and other systemic inflammatory disorders. There is some evidence suggesting the occurrence of pancreatitis following TCZ use. We aimed to determine the reporting of pancreatitis following TCZ use in comparison with other drugs using the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database. We extracted adverse event reports submitted to FAERS during 2013-2019. A reporting odds ratio (ROR) with the lower bound 95% confidence interval (CI) > 1 and a lower limit of a two-sided 95% interval of information component (IC
Identifiants
pubmed: 34552181
doi: 10.1038/s41598-021-98325-w
pii: 10.1038/s41598-021-98325-w
pmc: PMC8458491
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Receptors, Interleukin-6
0
tocilizumab
I031V2H011
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
18818Informations de copyright
© 2021. The Author(s).
Références
Drug Saf. 2007;30(6):551-4
pubmed: 17536881
Ochsner J. 2015 Spring;15(1):45-51
pubmed: 25829880
Br J Clin Pharmacol. 2011 Dec;72(6):905-8
pubmed: 21658092
Front Pharmacol. 2020 Jun 24;11:950
pubmed: 32670066
J Clin Pharm Ther. 2016 Dec;41(6):718-721
pubmed: 27670839
World J Gastroenterol. 2014 Nov 28;20(44):16529-34
pubmed: 25469020
Rheumatology (Oxford). 2021 May 14;60(5):2366-2374
pubmed: 33244600
J Med Virol. 2020 Oct;92(10):1791-1792
pubmed: 32314799
JOP. 2011 Nov 09;12(6):581-5
pubmed: 22072247
ACG Case Rep J. 2013 Oct 08;1(1):40-3
pubmed: 26157817
Pharmacotherapy. 2005 Aug;25(8):1044-54
pubmed: 16207094
Dig Dis Sci. 2010 Oct;55(10):2977-81
pubmed: 20499176
World J Gastroenterol. 2020 Jun 14;26(22):2902-2915
pubmed: 32587438
Arthritis Rheumatol. 2020 Jan;72(1):31-40
pubmed: 31469238
Clin Gastroenterol Hepatol. 2007 Jun;5(6):648-61; quiz 644
pubmed: 17395548
Drug Saf. 2017 Jul;40(7):571-582
pubmed: 28293864
Drug Saf. 2017 Jul;40(7):543-546
pubmed: 28560588
Rheumatology (Oxford). 2011 Oct;50(10):1908-15
pubmed: 21752873
Nat Biotechnol. 2016 Jul 12;34(7):697-700
pubmed: 27404875
Pancreas. 1996 Jul;13(1):100-9
pubmed: 8783341
Aliment Pharmacol Ther. 2006 Jan 1;23(1):185-90
pubmed: 16393296
Lancet Rheumatol. 2020 Aug;2(8):e474-e484
pubmed: 32835257
World J Gastrointest Pathophysiol. 2014 Nov 15;5(4):405-15
pubmed: 25400984
EClinicalMedicine. 2020 Jun 20;24:100418
pubmed: 32766537
Rheumatology (Oxford). 2013 Jul;52(7):1340-1
pubmed: 23315786
J Child Neurol. 2004 Jul;19(7):498-502
pubmed: 15526953
Drug Saf. 2008;31(10):823-37
pubmed: 18759507
Mod Rheumatol. 2009;19(4):351-7
pubmed: 19590933
Ther Innov Regul Sci. 2015 Jan;49(1):65-75
pubmed: 30222465
Stat Methods Med Res. 2013 Feb;22(1):57-69
pubmed: 21705438
PLoS One. 2015 Aug 11;10(8):e0135187
pubmed: 26262880
Scand J Gastroenterol. 2006 Dec;41(12):1484-90
pubmed: 17101581
Drug Saf. 2016 Jun;39(6):469-90
pubmed: 26951233
Eur J Clin Pharmacol. 1998 Jun;54(4):315-21
pubmed: 9696956
Clin Med Insights Arthritis Musculoskelet Disord. 2010 Dec 19;3:81-9
pubmed: 21234291
Am J Health Syst Pharm. 2008 Aug 1;65(15):1413-8
pubmed: 18653811
Sci Data. 2016 May 10;3:160026
pubmed: 27193236
Pharmacoepidemiol Drug Saf. 2009 Jun;18(6):427-36
pubmed: 19358225
Ther Adv Drug Saf. 2013 Oct;4(5):211-9
pubmed: 25114782